GATC Biotech is taking part in an EU funded research project to evaluate the safety of gene therapy in the treatment of monogenetic inherited diseases, such as immunodeficiencies, hemoglobinopathies, anemias and storage disorders.   Other contributors to the project comprise 18 academic groups and 3 companies from 9 European countries.

The aim of the resesarch project is an unbiased safety and efficiency evaluation of retroviral transgenesis for gene therapy of inherited deseases.

Central aspects of this evaluation are the molecular and clinical monitoring of model studies for genetic therapies as well as molecular studies in cell culture systems and animal models. The results will generate the basis for technology developments that enhance the safety of retroviral gene therapy.

In cooperation with the group of Prof. Christof von Kalle and Dr. Manfred Schmidt at the Departement of Internal Medicine and the Institute for Molecular Medicine, University Clinic Freiburg, GATC is developing a bioinformatic tool for comprehensive data storage and analysis of vector insertion sites in the genome (the LAM PCR database), allowing for mechanistic studies of transgene/host interactions.

The compilation of sequence data produced at GATC will generate the basis for the development of useable genetic vectors for the treatment of human desease without the risk of influencing the activity of oncogenes and tumor suppressor genes.

Find out more
about GATC's services:

CONSERT LAM-PCR sequencing

CONSERT LAM-PCR database

Petra and Anita ensure that a scientific sales manager
responsible for your territory will contact you immediately.